

Published by  
Ministry of Health, Labour and Welfare



Translated by  
Pharmaceuticals and Medical Devices Agency



---

*This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*

# Revision of Precautions

## Ivermectin

October 12, 2021

### **Therapeutic category**

Anthelmintics

### **Non-proprietary name**

Ivermectin

### **Safety measure**

Precautions should be revised in the package insert.

**Pharmaceuticals and Medical Devices Agency**

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan  
E-mail: [safety.info@pmda.go.jp](mailto:safety.info@pmda.go.jp)

Revision in line with the Instructions for Package Inserts of Prescription Drugs, PAB Notification No. 606 by the Director General of Pharmaceutical Affairs Bureau, MHW, dated April 25, 1997 (Old instructions): Revised language is underlined.

Current	Revision
<p>Important Precautions (N/A)</p>	<p>Important Precautions <u>Disturbed consciousness may occur. Patients should be adequately informed of the caution required when engaging in hazardous machine operation such as driving a car.</u></p>
<p>Adverse Reactions (N/A)</p>	<p>Adverse Reactions <u>Disturbed consciousness:</u> <u>If disturbed consciousness such as coma, depressed level of consciousness, or altered state of consciousness are observed, appropriate measures should be taken such as discontinuing this drug.</u></p>

Note: Designated as a drug requiring preparation of a Drug Guide for Patients

N/A: Not Applicable. No corresponding language is included in the current package insert.

**Pharmaceuticals and Medical Devices Agency**

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan  
E-mail: [safety.info@pmda.go.jp](mailto:safety.info@pmda.go.jp)